Open-label Adjunctive Zonisamide for Bipolar Disorder
Sponsor
Elan Pharmaceuticals (Industry)
Overall Status
Terminated
CT.gov ID
NCT00047567
Collaborator
(none)
20
Study Details
Study Description
Brief Summary
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date
:
Jul 1, 2002
Study Completion Date
:
Jul 1, 2002
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
6 Years
to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
-
Bipolar I/II
-
Average intelligence
-
Taking at least one, but no more than two mood stabilizers
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Elan Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00047567
Other Study ID Numbers:
- ELN-345-509
First Posted:
Oct 10, 2002
Last Update Posted:
Dec 14, 2015
Last Verified:
Dec 1, 2015
Keywords provided by ,
,
Additional relevant MeSH terms: